A story ran in The Age on August 5, 2010 titled Big Drug Deal. The byline referred to the deal between Phylogica and Medimmune with the claim that Phylogica had signed one of the biggest licencing deals of the year.
The discussion between Sharesontoast and Paul Watt appears to confirm the significance of the deal;
"[Watt] believed the deal to be as big as any achieved by an Australian Biotech." Thanks Sharesontoast.
Watt is a straight talker. I phoned Paul Watt in September 2009 and immediately decided to become a shareholder. Big Pharma are lining up to sign deals because they are afraid of missing out on a collaboration with the junior biotech with one of the world's leading biologic libraries.
Dr Doug Wilson (Executive Chairman), in an interview with Finance News Network in April 2010, describes Phylogica as having something "so profoundly unique". Wilson was formerly Global Head of Medicine for Boehringer Ingelheim.
Profoundly unique in the world of international drug companies may be profoundly valuable.
PYC Price at posting:
8.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)